Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for MRNA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
June 30, 2026 14.00M
March 31, 2026 17.00M
December 31, 2025 581.00M
September 30, 2025 -1.00M
June 30, 2025 9.00M
March 31, 2025 4.00M
December 31, 2024 -3.00M
September 30, 2024 11.00M
June 30, 2024 34.00M
March 31, 2024 14.00M
December 31, 2023 -109.00M
September 30, 2023 -58.00M
June 30, 2023 -668.00M
March 31, 2023 -542.00M
December 31, 2022 -438.00M
September 30, 2022 -1.041B
June 30, 2022 -1.327B
March 31, 2022 -642.00M
Date Value
December 31, 2021 -873.00M
September 30, 2021 -2.00M
June 30, 2021 -24.00M
March 31, 2021 26.00M
December 31, 2020 44.11M
September 30, 2020 29.73M
June 30, 2020 1.381B
March 31, 2020 578.05M
December 31, 2019 29.87M
September 30, 2019 15.81M
June 30, 2019 4.177M
March 31, 2019 0.293M
December 31, 2018 575.92M
September 30, 2018 -7.683M
June 30, 2018 108.62M
March 31, 2018 550.00M
December 31, 2017 1.539M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
BioNTech SE -126.88M
Kailera Therapeutics, Inc. 667.03M
Sarepta Therapeutics, Inc. 0.00
Replimune Group, Inc. 0.80M
Intellia Therapeutics, Inc. 196.12M